Key Segmentation
By Product
-
Kits
-
Assays
By Service
-
BRCA1/2 Testing
-
HRD Testing
-
HRR Testing
-
Others
By Application
-
Breast Cancer
-
Ovarian Cancer
-
Prostate Cancer
-
Others
By End Use
-
Hospitals and Clinics
-
Diagnostic Laboratories
-
Academic and Research Institutes
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include Myriad Genetics, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Foundation Medicine, Inc., QIAGEN N.V., Guardant Health, Inc., Agilent Technologies, Inc. and F. Hoffmann-La Roche AG.
Key opportunities include distributable HRD kits, liquid biopsy companion diagnostics and growing cancer testing programs in China, India and Brazil.
The major growth factor is the expansion of PARP inhibitor indications across ovarian, breast, prostate and pancreatic cancer, together with guideline-backed BRCA and HRD testing.
By Product, the Kits segment dominated the market in 2025 with an estimated 61.00% share, supported by validated, packaged workflows for BRCA and HRD testing.
North America dominated the market with a share of 43.00% in 2025, driven by early companion diagnostic approvals, sequencing access and oncology networks.
